Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.53 |
| ▸ | CTSD | P07339 | 1/20 | 0.51 |
| ▸ | REN | P00797 | 2/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.51 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.51 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.51 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.51 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.51 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8612027 | 0.96 | CTSS (0.54) | MEN1KMT2AATMCTSSCTSL | |
| SCHEMBL8530164 | 0.94 | PSEN1 (0.59) | CTSBCTSKCTSDRENPSEN1 | |
| SCHEMBL23170193 | 0.91 | MEN1 (0.55) | MEN1KMT2AATMCTSSCTSL | |
| SCHEMBL29861027 | 0.91 | CTSD (0.54) | MEN1KMT2AATMCTSSCTSL | |
| SCHEMBL27738325 | 0.91 | KLK5 (0.62) | MEN1KMT2AATMCTSSCTSL | |
| SCHEMBL7418843 | 0.91 | KLK5 (0.62) | MEN1KMT2AATMCTSSCTSL | |
| SCHEMBL9887475 | 0.91 | KLK5 (0.62) | MEN1KMT2AATMCTSSCTSL | |
| SCHEMBL18257547 | 0.90 | CTSD (0.56) | MEN1KMT2ACTSSCTSLCTSB | |
| SCHEMBL23616314 | 0.90 | CTSD (0.56) | MEN1KMT2ACTSSCTSLCTSB | |
| SCHEMBL24049735 | 0.90 | CTSK (0.57) | MEN1KMT2ACTSBCTSKPSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396497-B2 | Proteasome inhibitors | NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION (US) | 2022-07-26 | — | — | US | disclosed |
| US-20210363119-A1 | PROTEASOME INHIBITORS | NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION | 2021-11-25 | — | — | US | disclosed |
| US-20170260230-A1 | COMPUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-8716322-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-7687456-B2 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090203698-A1 | Compounds for Enzyme Inhibition | PROTEOLIX, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363119-A1 | PROTEASOME INHIBITORS | TP53, CDKN1A, PSME1 | MEN1 2842/4885KMT2A 1723/4885ATM 498/4885 |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, PSMB1, PSMB3 | MEN1 3875/4885KMT2A 3318/4885ATM 4632/4885 |
| US-20170260230-A1 | COMPUNDS FOR ENZYME INHIBITION | ANPEP, PSMB1, CPN1 | MEN1 2628/4885KMT2A 2930/4885ATM 4834/4885 |
| US-20090203698-A1 | Compounds for Enzyme Inhibition | ANPEP, HPN, DNPEP | MEN1 3505/4885KMT2A 3038/4885ATM 4793/4885 |
| US-11396497-B2 | Proteasome inhibitors | TP53, CDKN1A, PSME1 | MEN1 2842/4885KMT2A 1723/4885ATM 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.